Professional Development

These simple, clever tips crystallize several years’ worth of experience in the development and operation of a modern eye hospital. You may know some of them already – but there’s likely at least one you don’t.

Can Hoya IOLs regain market position after being withdrawn for the best part of a year?

What is SCHWIND eye-tech-solutions known for? We develop, produce and market a comprehensive product portfolio for the treatment of ametropia and corneal diseases. This includes diagnostic systems, software modules for individual treatment planning, and nanosecond and excimer laser systems.

With an ever-growing market and new treatment options on hand, presbyopia offers an attractive business proposition. Understanding the patient and building your practice around her/him is key to success. Here’s how we have done it.

A stark picture of an overstretched, fragile service, often at odds with hospital management, is painted in a recent RCO report. What can be done?

Why the pharmaceutical industry is making acquisitions in ophthalmology – and why it won’t stop. The world’s pharmaceutical companies have fallen heavily for the charms of ophthalmology in recent times, with a string of acquisitions and product launches, including: